相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Mount Sinai and King Saud University Medical City announced a three-year collaboration to study familial inflammatory bowel disease patterns in Saudi families with multiple affected members. - The initiative will collect biospecimens and clinical data to identify exposure and biological markers that drive IBD disease mechanisms and outcomes in high-risk families. - Researchers aim to accelerate development of personalized diagnostics and therapies by combining multi-omics profiling with detailed family pedigrees and clinical histories. - The collaboration seeks to enable earlier risk assessment and more precise treatment strategies for IBD patients worldwide through advanced biomarker discovery.
- Sensory Cloud's SC0023 therapeutic aerosol demonstrated a 34% placebo-adjusted cough rate reduction in patients with refractory chronic cough during the Phase II REACH trial. - The study revealed persistent cough suppression lasting several weeks after dosing, despite the treatment's three-hour endogenous ion clearance time. - Chronic cough affects an estimated 10% of the adult global population, representing a major unmet healthcare need according to trial investigators. - The company plans to advance SC0023 into a follow-up Phase II study across multiple centers in Belfast, Ireland, and London, UK.
